Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward has announced its 2025 Annual Meeting of Shareholders to be held on August 1, 2025 at their Marlborough, MA headquarters. The proxy statement outlines 8 key proposals requiring shareholder approval:
- Reelection of three Class II directors to serve until 2028
- Ratification of compensation for new President and co-CEO Mark Grant
- Approval of Board Chairperson annual fees
- Approval of 2025 Incentive Compensation Plan
- Ratification of equity compensation for board member Randel E. Richner
- Amendments to increase authorized share capital
- Reappointment of Ernst & Young as independent auditors
- Advisory "Say-on-Pay" vote on executive compensation
The Board recommends voting "FOR" all proposals. Most proposals require a simple majority approval, while the CEO compensation proposal requires additional majority conditions excluding controlling shareholders. The record date is June 23, 2025, and shareholders must submit proxies by July 31, 2025.
Lifeward has received SEC approval for its Form S-1 registration statement, which became effective on June 25, 2025, at 9:00 A.M. The Form S-1 (File Number: 333-288172) marks a significant milestone as it indicates the company's intention to conduct an initial public offering (IPO).
This Notice of Effectiveness (EFFECT filing) confirms that Lifeward can now proceed with its planned public offering of securities. The company, identified by CIK number 0001607962, has completed the SEC review process and received regulatory clearance to move forward with its IPO plans.
Key points for investors:
- Form S-1 registration statement is now active
- Company can commence its IPO process
- Trading symbol will be LFWD
- Securities can be offered to the public following the effectiveness date
Lifeward has filed an amended S-1 registration statement for a proposed public offering of up to 4,000,000 ordinary shares at an assumed price of $1.07 per share, along with accompanying warrants. The offering includes:
- Warrants to purchase up to 4,000,000 ordinary shares at $1.07 per exercise price
- Pre-funded warrants available for investors who would exceed 4.99% ownership
- Placement Agent Warrants to purchase up to 240,000 ordinary shares
- Total of up to 8,240,000 ordinary shares issuable upon exercise of all warrants
H.C. Wainwright & Co. is acting as exclusive placement agent, receiving a 7% cash fee plus 1% management fee. The offering will terminate on July 30, 2025 unless ended earlier. Lifeward trades on Nasdaq Capital Market under symbol "LFWD" and qualifies as a smaller reporting company. The company is headquartered in Marlborough, MA with incorporation in Israel. Proceeds will be immediately available for use with no minimum offering amount required.
Lifeward, an Israeli medical device company (NASDAQ: LFWD), has filed an S-1 registration statement for a public offering of up to 4,000,000 ordinary shares and warrants. The offering includes:
- Ordinary shares with accompanying warrants at an assumed price of $1.07 per unit
- Pre-funded warrants with accompanying warrants for investors exceeding 4.99%/9.99% ownership threshold
- Warrants exercisable at $1.07 per share with 5-year term
- 240,000 placement agent warrants (6% of offering)
Key details: The company is a smaller reporting company and non-accelerated filer. The offering will terminate on July 30, 2025, with no minimum offering amount required. Proceeds will be immediately available for use. The placement agent will receive a 7% cash fee plus 1% management fee. Trading warrants will not be listed on any exchange.
Risks include: No escrow arrangements, no minimum offering amount, immediate use of proceeds without guarantee of achieving business objectives.